Substance / Medication

Bendamustine

Overview

Active Ingredient
bendamustine
RxNorm CUI
134547

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
1
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy and safety of polatuzumab-vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: A systematic review and meta-analysis.
Farooqi Hanzala Ahmed, Saffi Ullah Muhammad, Raza Ahmed et al. · Crit Rev Oncol Hematol · 2025
PMID: 39793679Meta-Analysis
BR (bendamustine plus rituximab) versus R-CHOP for patients with indolent B-cell lymphomas: a systematic review and Meta-analysis.
Ou Wenxin, Jiang Tiantian, Tang Xiaoqiong · J Chemother · 2023
PMID: 35220927Meta-Analysis
Bendamustine-associated infections-systematic review and meta-analysis of randomized controlled trials.
Gafter-Gvili Anat, Gurion Ronit, Raanani Pia et al. · Hematol Oncol · 2017
PMID: 27734524Meta-Analysis
Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia.
Vidal Liat, Gafter-Gvili Anat, Gurion Ronit et al. · Cochrane Database Syst Rev · 2012
PMID: 22972131Meta-AnalysisFull text (PMC)
Population Pharmacokinetic and Exposure-Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma.
Gisleskog Per Olsson, Valenzuela Belén, Treijtel Nicoline et al. · CPT Pharmacometrics Syst Pharmacol · 2025
PMID: 40613748RCTFull text (PMC)
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.
Wang Michael, Salek David, Belada David et al. · J Clin Oncol · 2025
PMID: 40311141RCTFull text (PMC)
Impact of best response to ibrutinib plus Bendamustine and rituximab on PFS in MCL: a secondary analysis of SHINE.
Mishima Yuko, Hashimoto Daigo, Ichii Michiko et al. · Ann Hematol · 2025
PMID: 40940567RCTFull text (PMC)
Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study.
Flowers Christopher R, Matasar Matthew J, Herrera Alex F et al. · Haematologica · 2024
PMID: 37767550RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Bendamustine (substance)
SNOMED CT
428012008
UMLS CUI
C0525079
RxNorm CUI
134547

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.